nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CYP1A1—Clobetasol propionate—psoriasis	0.0661	0.149	CbGbCtD
Dasatinib—CYP1A1—Methoxsalen—psoriasis	0.0347	0.0782	CbGbCtD
Dasatinib—CYP3A5—Beclomethasone—psoriasis	0.0301	0.0677	CbGbCtD
Dasatinib—CYP1A2—Clobetasol propionate—psoriasis	0.0295	0.0665	CbGbCtD
Dasatinib—CYP1A1—Cholecalciferol—psoriasis	0.023	0.0518	CbGbCtD
Dasatinib—CYP1B1—Dexamethasone—psoriasis	0.0227	0.0511	CbGbCtD
Dasatinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0216	0.0487	CbGbCtD
Dasatinib—ABCG2—Hydrocortisone—psoriasis	0.0173	0.0391	CbGbCtD
Dasatinib—ABCG2—Cyclosporine—psoriasis	0.0164	0.0369	CbGbCtD
Dasatinib—CYP1A2—Methoxsalen—psoriasis	0.0155	0.0349	CbGbCtD
Dasatinib—FMO3—sweat—psoriasis	0.0135	0.163	CbGeAlD
Dasatinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.012	0.027	CbGbCtD
Dasatinib—ABCG2—Dexamethasone—psoriasis	0.0108	0.0243	CbGbCtD
Dasatinib—CYP3A4—Calcitriol—psoriasis	0.0105	0.0235	CbGbCtD
Dasatinib—CYP1A1—Dexamethasone—psoriasis	0.00996	0.0224	CbGbCtD
Dasatinib—CYP3A5—Hydrocortisone—psoriasis	0.00961	0.0216	CbGbCtD
Dasatinib—CYP3A5—Cyclosporine—psoriasis	0.00908	0.0204	CbGbCtD
Dasatinib—ABCG2—Methotrexate—psoriasis	0.00867	0.0195	CbGbCtD
Dasatinib—CYP3A4—Methoxsalen—psoriasis	0.00813	0.0183	CbGbCtD
Dasatinib—ABCB1—Mycophenolate mofetil—psoriasis	0.00779	0.0175	CbGbCtD
Dasatinib—ABCB1—Betamethasone—psoriasis	0.00669	0.0151	CbGbCtD
Dasatinib—ABCB1—Prednisolone—psoriasis	0.0066	0.0149	CbGbCtD
Dasatinib—ABCB1—Hydrocortisone—psoriasis	0.00626	0.0141	CbGbCtD
Dasatinib—ABCB1—Prednisone—psoriasis	0.00623	0.014	CbGbCtD
Dasatinib—PTK6—skin epidermis—psoriasis	0.00613	0.0736	CbGeAlD
Dasatinib—CYP3A5—Dexamethasone—psoriasis	0.00598	0.0135	CbGbCtD
Dasatinib—ABCB1—Cyclosporine—psoriasis	0.00591	0.0133	CbGbCtD
Dasatinib—RIPK2—synovial membrane of synovial joint—psoriasis	0.00568	0.0681	CbGeAlD
Dasatinib—CYP3A4—Cholecalciferol—psoriasis	0.00539	0.0121	CbGbCtD
Dasatinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00467	0.0105	CbGbCtD
Dasatinib—CYP3A4—Triamcinolone—psoriasis	0.00467	0.0105	CbGbCtD
Dasatinib—CYP3A4—Betamethasone—psoriasis	0.00401	0.00902	CbGbCtD
Dasatinib—CYP3A4—Prednisolone—psoriasis	0.00395	0.0089	CbGbCtD
Dasatinib—ABCB1—Dexamethasone—psoriasis	0.00389	0.00876	CbGbCtD
Dasatinib—CYP3A4—Hydrocortisone—psoriasis	0.00375	0.00844	CbGbCtD
Dasatinib—CYP3A4—Prednisone—psoriasis	0.00373	0.0084	CbGbCtD
Dasatinib—CYP3A4—Cyclosporine—psoriasis	0.00354	0.00797	CbGbCtD
Dasatinib—ABCB1—Methotrexate—psoriasis	0.00313	0.00704	CbGbCtD
Dasatinib—RIPK2—endothelium—psoriasis	0.00264	0.0317	CbGeAlD
Dasatinib—TEC—tendon—psoriasis	0.00234	0.0281	CbGeAlD
Dasatinib—CYP3A4—Dexamethasone—psoriasis	0.00233	0.00525	CbGbCtD
Dasatinib—EPHB4—endothelium—psoriasis	0.00223	0.0268	CbGeAlD
Dasatinib—KIT—skin epidermis—psoriasis	0.00213	0.0256	CbGeAlD
Dasatinib—BMX—skin of body—psoriasis	0.00203	0.0243	CbGeAlD
Dasatinib—PTK6—skin of body—psoriasis	0.0019	0.0228	CbGeAlD
Dasatinib—SRC—endothelium—psoriasis	0.0019	0.0228	CbGeAlD
Dasatinib—EPHB1—tendon—psoriasis	0.00184	0.022	CbGeAlD
Dasatinib—STAT5B—skin of body—psoriasis	0.0018	0.0216	CbGeAlD
Dasatinib—KIT—endothelium—psoriasis	0.00155	0.0186	CbGeAlD
Dasatinib—SIK3—tendon—psoriasis	0.00123	0.0148	CbGeAlD
Dasatinib—STK35—skin of body—psoriasis	0.00122	0.0147	CbGeAlD
Dasatinib—CSK—skin of body—psoriasis	0.00122	0.0146	CbGeAlD
Dasatinib—ZAK—tendon—psoriasis	0.00114	0.0137	CbGeAlD
Dasatinib—RIPK2—skin of body—psoriasis	0.00113	0.0135	CbGeAlD
Dasatinib—CYP1A1—skin epidermis—psoriasis	0.00111	0.0133	CbGeAlD
Dasatinib—SIK1—skin of body—psoriasis	0.0011	0.0132	CbGeAlD
Dasatinib—BTK—tendon—psoriasis	0.00109	0.0131	CbGeAlD
Dasatinib—ERBB3—skin of body—psoriasis	0.00108	0.013	CbGeAlD
Dasatinib—TESK1—tendon—psoriasis	0.00101	0.0121	CbGeAlD
Dasatinib—MAPK14—skin of body—psoriasis	0.00101	0.0121	CbGeAlD
Dasatinib—STK36—tendon—psoriasis	0.000994	0.0119	CbGeAlD
Dasatinib—CSK—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000977	0.181	CbGdCrCtD
Dasatinib—JAK2—skin of body—psoriasis	0.000947	0.0114	CbGeAlD
Dasatinib—FYN—skin of body—psoriasis	0.000934	0.0112	CbGeAlD
Dasatinib—STK35—tendon—psoriasis	0.000932	0.0112	CbGeAlD
Dasatinib—CSK—tendon—psoriasis	0.000925	0.0111	CbGeAlD
Dasatinib—HCK—tendon—psoriasis	0.000914	0.011	CbGeAlD
Dasatinib—MAP3K3—skin of body—psoriasis	0.000912	0.011	CbGeAlD
Dasatinib—ABL2—tendon—psoriasis	0.000908	0.0109	CbGeAlD
Dasatinib—EPHB6—skin of body—psoriasis	0.000872	0.0105	CbGeAlD
Dasatinib—RIPK2—tendon—psoriasis	0.000859	0.0103	CbGeAlD
Dasatinib—SIK1—tendon—psoriasis	0.000839	0.0101	CbGeAlD
Dasatinib—EPHA4—tendon—psoriasis	0.00083	0.00997	CbGeAlD
Dasatinib—SRC—skin of body—psoriasis	0.000811	0.00973	CbGeAlD
Dasatinib—MAPK14—tendon—psoriasis	0.000766	0.00919	CbGeAlD
Dasatinib—FGR—tendon—psoriasis	0.000762	0.00915	CbGeAlD
Dasatinib—CSF1R—skin of body—psoriasis	0.000728	0.00874	CbGeAlD
Dasatinib—EPHB4—tendon—psoriasis	0.000726	0.00871	CbGeAlD
Dasatinib—JAK2—tendon—psoriasis	0.000721	0.00865	CbGeAlD
Dasatinib—EPHA2—tendon—psoriasis	0.000712	0.00855	CbGeAlD
Dasatinib—FYN—tendon—psoriasis	0.000711	0.00853	CbGeAlD
Dasatinib—MAP4K5—tendon—psoriasis	0.000695	0.00834	CbGeAlD
Dasatinib—MAP3K3—tendon—psoriasis	0.000695	0.00834	CbGeAlD
Dasatinib—EPHB6—tendon—psoriasis	0.000664	0.00797	CbGeAlD
Dasatinib—KIT—skin of body—psoriasis	0.000661	0.00793	CbGeAlD
Dasatinib—PDGFRB—skin of body—psoriasis	0.000645	0.00775	CbGeAlD
Dasatinib—YES1—tendon—psoriasis	0.000641	0.0077	CbGeAlD
Dasatinib—PDGFRA—tendon—psoriasis	0.000629	0.00755	CbGeAlD
Dasatinib—ABL1—skin of body—psoriasis	0.000575	0.00691	CbGeAlD
Dasatinib—MAP2K5—tendon—psoriasis	0.000568	0.00681	CbGeAlD
Dasatinib—CSF1R—tendon—psoriasis	0.000554	0.00665	CbGeAlD
Dasatinib—PDGFRB—tendon—psoriasis	0.000491	0.0059	CbGeAlD
Dasatinib—CYP1B1—skin of body—psoriasis	0.000487	0.00585	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Clobetasol propionate—psoriasis	0.000453	0.084	CbGdCrCtD
Dasatinib—ABL1—tendon—psoriasis	0.000438	0.00526	CbGeAlD
Dasatinib—CYP1B1—tendon—psoriasis	0.000371	0.00445	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Fluocinonide—psoriasis	0.000363	0.0673	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Beclomethasone—psoriasis	0.000363	0.0673	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000353	0.0654	CbGdCrCtD
Dasatinib—CYP1A1—skin of body—psoriasis	0.000344	0.00413	CbGeAlD
Dasatinib—TESK1—Dexamethasone—Clobetasol propionate—psoriasis	0.000184	0.0341	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Clobetasol propionate—psoriasis	0.000184	0.0341	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Betamethasone—psoriasis	0.000165	0.0307	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Dexamethasone—psoriasis	0.000165	0.0307	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Triamcinolone—psoriasis	0.000162	0.03	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Prednisone—psoriasis	0.000153	0.0284	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Prednisolone—psoriasis	0.00015	0.0278	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Fluocinonide—psoriasis	0.000148	0.0273	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Beclomethasone—psoriasis	0.000148	0.0273	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Fluocinonide—psoriasis	0.000148	0.0273	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Beclomethasone—psoriasis	0.000148	0.0273	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000143	0.0266	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000143	0.0266	CbGdCrCtD
Dasatinib—PKMYT1—Danazol—Hydrocortisone—psoriasis	0.000101	0.0187	CbGdCrCtD
Dasatinib—PKMYT1—Danazol—Prednisone—psoriasis	8.71e-05	0.0161	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Hydrocortisone—psoriasis	7.24e-05	0.0134	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Hydrocortisone—psoriasis	7.24e-05	0.0134	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Dexamethasone—psoriasis	6.73e-05	0.0125	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Betamethasone—psoriasis	6.73e-05	0.0125	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Triamcinolone—psoriasis	6.57e-05	0.0122	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Triamcinolone—psoriasis	6.57e-05	0.0122	CbGdCrCtD
Dasatinib—Urticaria—Cyclosporine—psoriasis	6.28e-05	0.000248	CcSEcCtD
Dasatinib—Myalgia—Dexamethasone—psoriasis	6.26e-05	0.000247	CcSEcCtD
Dasatinib—Myalgia—Betamethasone—psoriasis	6.26e-05	0.000247	CcSEcCtD
Dasatinib—Body temperature increased—Cyclosporine—psoriasis	6.25e-05	0.000246	CcSEcCtD
Dasatinib—Abdominal pain—Cyclosporine—psoriasis	6.25e-05	0.000246	CcSEcCtD
Dasatinib—Anxiety—Dexamethasone—psoriasis	6.24e-05	0.000246	CcSEcCtD
Dasatinib—Anxiety—Betamethasone—psoriasis	6.24e-05	0.000246	CcSEcCtD
Dasatinib—TESK1—Dexamethasone—Prednisone—psoriasis	6.24e-05	0.0116	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisone—psoriasis	6.24e-05	0.0116	CbGdCrCtD
Dasatinib—Vomiting—Mycophenolic acid—psoriasis	6.21e-05	0.000245	CcSEcCtD
Dasatinib—Discomfort—Dexamethasone—psoriasis	6.19e-05	0.000244	CcSEcCtD
Dasatinib—Discomfort—Betamethasone—psoriasis	6.19e-05	0.000244	CcSEcCtD
Dasatinib—Dyspepsia—Hydrocortisone—psoriasis	6.18e-05	0.000244	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—psoriasis	6.18e-05	0.000244	CcSEcCtD
Dasatinib—Rash—Mycophenolic acid—psoriasis	6.16e-05	0.000243	CcSEcCtD
Dasatinib—Dermatitis—Mycophenolic acid—psoriasis	6.15e-05	0.000243	CcSEcCtD
Dasatinib—Pain—Prednisolone—psoriasis	6.15e-05	0.000243	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—psoriasis	6.15e-05	0.000242	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—psoriasis	6.15e-05	0.000242	CcSEcCtD
Dasatinib—Urticaria—Mycophenolate mofetil—psoriasis	6.13e-05	0.000242	CcSEcCtD
Dasatinib—Headache—Mycophenolic acid—psoriasis	6.12e-05	0.000241	CcSEcCtD
Dasatinib—Decreased appetite—Hydrocortisone—psoriasis	6.11e-05	0.000241	CcSEcCtD
Dasatinib—Abdominal pain—Mycophenolate mofetil—psoriasis	6.09e-05	0.00024	CcSEcCtD
Dasatinib—Body temperature increased—Mycophenolate mofetil—psoriasis	6.09e-05	0.00024	CcSEcCtD
Dasatinib—TESK1—Dexamethasone—Prednisolone—psoriasis	6.09e-05	0.0113	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisolone—psoriasis	6.09e-05	0.0113	CbGdCrCtD
Dasatinib—Urinary tract disorder—Methotrexate—psoriasis	6.07e-05	0.000239	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.06e-05	0.000239	CcSEcCtD
Dasatinib—Fatigue—Hydrocortisone—psoriasis	6.06e-05	0.000239	CcSEcCtD
Dasatinib—Vision blurred—Prednisone—psoriasis	6.04e-05	0.000238	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—psoriasis	6.03e-05	0.000238	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.03e-05	0.000238	CcSEcCtD
Dasatinib—Pain—Hydrocortisone—psoriasis	6.01e-05	0.000237	CcSEcCtD
Dasatinib—Oedema—Dexamethasone—psoriasis	6e-05	0.000237	CcSEcCtD
Dasatinib—Oedema—Betamethasone—psoriasis	6e-05	0.000237	CcSEcCtD
Dasatinib—Insomnia—Triamcinolone—psoriasis	5.98e-05	0.000236	CcSEcCtD
Dasatinib—Infection—Dexamethasone—psoriasis	5.96e-05	0.000235	CcSEcCtD
Dasatinib—Infection—Betamethasone—psoriasis	5.96e-05	0.000235	CcSEcCtD
Dasatinib—Ill-defined disorder—Prednisone—psoriasis	5.94e-05	0.000234	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisolone—psoriasis	5.93e-05	0.000234	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—psoriasis	5.92e-05	0.000234	CcSEcCtD
Dasatinib—Anaemia—Prednisone—psoriasis	5.92e-05	0.000233	CcSEcCtD
Dasatinib—Shock—Dexamethasone—psoriasis	5.9e-05	0.000233	CcSEcCtD
Dasatinib—Shock—Betamethasone—psoriasis	5.9e-05	0.000233	CcSEcCtD
Dasatinib—Dyspnoea—Triamcinolone—psoriasis	5.9e-05	0.000233	CcSEcCtD
Dasatinib—Nervous system disorder—Dexamethasone—psoriasis	5.89e-05	0.000232	CcSEcCtD
Dasatinib—Nervous system disorder—Betamethasone—psoriasis	5.89e-05	0.000232	CcSEcCtD
Dasatinib—Thrombocytopenia—Betamethasone—psoriasis	5.88e-05	0.000232	CcSEcCtD
Dasatinib—Thrombocytopenia—Dexamethasone—psoriasis	5.88e-05	0.000232	CcSEcCtD
Dasatinib—Tachycardia—Betamethasone—psoriasis	5.86e-05	0.000231	CcSEcCtD
Dasatinib—Tachycardia—Dexamethasone—psoriasis	5.86e-05	0.000231	CcSEcCtD
Dasatinib—Hypersensitivity—Cyclosporine—psoriasis	5.82e-05	0.00023	CcSEcCtD
Dasatinib—Dyspepsia—Triamcinolone—psoriasis	5.82e-05	0.00023	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—psoriasis	5.81e-05	0.000229	CcSEcCtD
Dasatinib—Nausea—Mycophenolic acid—psoriasis	5.8e-05	0.000229	CcSEcCtD
Dasatinib—Hyperhidrosis—Betamethasone—psoriasis	5.8e-05	0.000229	CcSEcCtD
Dasatinib—Hyperhidrosis—Dexamethasone—psoriasis	5.8e-05	0.000229	CcSEcCtD
Dasatinib—Feeling abnormal—Hydrocortisone—psoriasis	5.79e-05	0.000228	CcSEcCtD
Dasatinib—Malaise—Prednisone—psoriasis	5.77e-05	0.000228	CcSEcCtD
Dasatinib—Vertigo—Prednisone—psoriasis	5.75e-05	0.000227	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—psoriasis	5.75e-05	0.000227	CcSEcCtD
Dasatinib—Gastrointestinal pain—Hydrocortisone—psoriasis	5.74e-05	0.000226	CcSEcCtD
Dasatinib—Syncope—Prednisone—psoriasis	5.74e-05	0.000226	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—psoriasis	5.73e-05	0.000226	CcSEcCtD
Dasatinib—Anorexia—Dexamethasone—psoriasis	5.72e-05	0.000226	CcSEcCtD
Dasatinib—Anorexia—Betamethasone—psoriasis	5.72e-05	0.000226	CcSEcCtD
Dasatinib—Urticaria—Prednisolone—psoriasis	5.71e-05	0.000225	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—psoriasis	5.71e-05	0.000225	CcSEcCtD
Dasatinib—Fatigue—Triamcinolone—psoriasis	5.7e-05	0.000225	CcSEcCtD
Dasatinib—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.68e-05	0.000224	CcSEcCtD
Dasatinib—Asthenia—Cyclosporine—psoriasis	5.67e-05	0.000224	CcSEcCtD
Dasatinib—Pain—Triamcinolone—psoriasis	5.66e-05	0.000223	CcSEcCtD
Dasatinib—Loss of consciousness—Prednisone—psoriasis	5.63e-05	0.000222	CcSEcCtD
Dasatinib—Hypotension—Betamethasone—psoriasis	5.61e-05	0.000221	CcSEcCtD
Dasatinib—Hypotension—Dexamethasone—psoriasis	5.61e-05	0.000221	CcSEcCtD
Dasatinib—Pruritus—Cyclosporine—psoriasis	5.59e-05	0.00022	CcSEcCtD
Dasatinib—Urticaria—Hydrocortisone—psoriasis	5.58e-05	0.00022	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—psoriasis	5.58e-05	0.00022	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—psoriasis	5.55e-05	0.000219	CcSEcCtD
Dasatinib—Abdominal pain—Hydrocortisone—psoriasis	5.55e-05	0.000219	CcSEcCtD
Dasatinib—Body temperature increased—Hydrocortisone—psoriasis	5.55e-05	0.000219	CcSEcCtD
Dasatinib—Convulsion—Prednisone—psoriasis	5.55e-05	0.000219	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—psoriasis	5.54e-05	0.000218	CcSEcCtD
Dasatinib—Asthenia—Mycophenolate mofetil—psoriasis	5.53e-05	0.000218	CcSEcCtD
Dasatinib—Hypertension—Prednisone—psoriasis	5.53e-05	0.000218	CcSEcCtD
Dasatinib—Chills—Methotrexate—psoriasis	5.52e-05	0.000218	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Betamethasone—psoriasis	5.47e-05	0.000216	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.47e-05	0.000216	CcSEcCtD
Dasatinib—Pruritus—Mycophenolate mofetil—psoriasis	5.45e-05	0.000215	CcSEcCtD
Dasatinib—Myalgia—Prednisone—psoriasis	5.45e-05	0.000215	CcSEcCtD
Dasatinib—Arthralgia—Prednisone—psoriasis	5.45e-05	0.000215	CcSEcCtD
Dasatinib—Feeling abnormal—Triamcinolone—psoriasis	5.45e-05	0.000215	CcSEcCtD
Dasatinib—Anxiety—Prednisone—psoriasis	5.43e-05	0.000214	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—psoriasis	5.43e-05	0.000214	CcSEcCtD
Dasatinib—Insomnia—Betamethasone—psoriasis	5.43e-05	0.000214	CcSEcCtD
Dasatinib—Insomnia—Dexamethasone—psoriasis	5.43e-05	0.000214	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.41e-05	0.000213	CcSEcCtD
Dasatinib—Diarrhoea—Cyclosporine—psoriasis	5.41e-05	0.000213	CcSEcCtD
Dasatinib—Discomfort—Prednisone—psoriasis	5.39e-05	0.000212	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—psoriasis	5.39e-05	0.000212	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—psoriasis	5.35e-05	0.000211	CcSEcCtD
Dasatinib—Erythema—Methotrexate—psoriasis	5.35e-05	0.000211	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisolone—psoriasis	5.3e-05	0.000209	CcSEcCtD
Dasatinib—Dyspepsia—Dexamethasone—psoriasis	5.28e-05	0.000208	CcSEcCtD
Dasatinib—Dyspepsia—Betamethasone—psoriasis	5.28e-05	0.000208	CcSEcCtD
Dasatinib—Diarrhoea—Mycophenolate mofetil—psoriasis	5.28e-05	0.000208	CcSEcCtD
Dasatinib—Urticaria—Triamcinolone—psoriasis	5.25e-05	0.000207	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—psoriasis	5.24e-05	0.000207	CcSEcCtD
Dasatinib—Body temperature increased—Triamcinolone—psoriasis	5.23e-05	0.000206	CcSEcCtD
Dasatinib—Dizziness—Cyclosporine—psoriasis	5.23e-05	0.000206	CcSEcCtD
Dasatinib—Oedema—Prednisone—psoriasis	5.23e-05	0.000206	CcSEcCtD
Dasatinib—Decreased appetite—Betamethasone—psoriasis	5.22e-05	0.000206	CcSEcCtD
Dasatinib—Decreased appetite—Dexamethasone—psoriasis	5.22e-05	0.000206	CcSEcCtD
Dasatinib—Infection—Prednisone—psoriasis	5.19e-05	0.000205	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Dexamethasone—psoriasis	5.18e-05	0.000204	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Betamethasone—psoriasis	5.18e-05	0.000204	CcSEcCtD
Dasatinib—Hypersensitivity—Hydrocortisone—psoriasis	5.18e-05	0.000204	CcSEcCtD
Dasatinib—Fatigue—Betamethasone—psoriasis	5.17e-05	0.000204	CcSEcCtD
Dasatinib—Fatigue—Dexamethasone—psoriasis	5.17e-05	0.000204	CcSEcCtD
Dasatinib—Shock—Prednisone—psoriasis	5.14e-05	0.000203	CcSEcCtD
Dasatinib—Pain—Betamethasone—psoriasis	5.13e-05	0.000202	CcSEcCtD
Dasatinib—Pain—Dexamethasone—psoriasis	5.13e-05	0.000202	CcSEcCtD
Dasatinib—Nervous system disorder—Prednisone—psoriasis	5.13e-05	0.000202	CcSEcCtD
Dasatinib—Tachycardia—Prednisone—psoriasis	5.1e-05	0.000201	CcSEcCtD
Dasatinib—Dizziness—Mycophenolate mofetil—psoriasis	5.1e-05	0.000201	CcSEcCtD
Dasatinib—Skin disorder—Prednisone—psoriasis	5.08e-05	0.0002	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisone—psoriasis	5.05e-05	0.000199	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—psoriasis	5.04e-05	0.000199	CcSEcCtD
Dasatinib—Asthenia—Hydrocortisone—psoriasis	5.04e-05	0.000199	CcSEcCtD
Dasatinib—Vomiting—Cyclosporine—psoriasis	5.03e-05	0.000198	CcSEcCtD
Dasatinib—Rash—Cyclosporine—psoriasis	4.98e-05	0.000196	CcSEcCtD
Dasatinib—Anorexia—Prednisone—psoriasis	4.98e-05	0.000196	CcSEcCtD
Dasatinib—Dermatitis—Cyclosporine—psoriasis	4.98e-05	0.000196	CcSEcCtD
Dasatinib—Pruritus—Hydrocortisone—psoriasis	4.97e-05	0.000196	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—psoriasis	4.97e-05	0.000196	CcSEcCtD
Dasatinib—Headache—Cyclosporine—psoriasis	4.95e-05	0.000195	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—psoriasis	4.95e-05	0.000195	CcSEcCtD
Dasatinib—Feeling abnormal—Betamethasone—psoriasis	4.95e-05	0.000195	CcSEcCtD
Dasatinib—Feeling abnormal—Dexamethasone—psoriasis	4.95e-05	0.000195	CcSEcCtD
Dasatinib—Gastrointestinal pain—Betamethasone—psoriasis	4.91e-05	0.000193	CcSEcCtD
Dasatinib—Gastrointestinal pain—Dexamethasone—psoriasis	4.91e-05	0.000193	CcSEcCtD
Dasatinib—Vomiting—Mycophenolate mofetil—psoriasis	4.9e-05	0.000193	CcSEcCtD
Dasatinib—Hypersensitivity—Triamcinolone—psoriasis	4.87e-05	0.000192	CcSEcCtD
Dasatinib—Rash—Mycophenolate mofetil—psoriasis	4.86e-05	0.000192	CcSEcCtD
Dasatinib—Dermatitis—Mycophenolate mofetil—psoriasis	4.86e-05	0.000192	CcSEcCtD
Dasatinib—Headache—Mycophenolate mofetil—psoriasis	4.83e-05	0.00019	CcSEcCtD
Dasatinib—Malaise—Methotrexate—psoriasis	4.83e-05	0.00019	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—psoriasis	4.81e-05	0.00019	CcSEcCtD
Dasatinib—Diarrhoea—Hydrocortisone—psoriasis	4.81e-05	0.00019	CcSEcCtD
Dasatinib—Urticaria—Dexamethasone—psoriasis	4.77e-05	0.000188	CcSEcCtD
Dasatinib—Urticaria—Betamethasone—psoriasis	4.77e-05	0.000188	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Prednisone—psoriasis	4.76e-05	0.000188	CcSEcCtD
Dasatinib—Dizziness—Prednisolone—psoriasis	4.76e-05	0.000188	CcSEcCtD
Dasatinib—Asthenia—Triamcinolone—psoriasis	4.75e-05	0.000187	CcSEcCtD
Dasatinib—Abdominal pain—Dexamethasone—psoriasis	4.74e-05	0.000187	CcSEcCtD
Dasatinib—Abdominal pain—Betamethasone—psoriasis	4.74e-05	0.000187	CcSEcCtD
Dasatinib—Body temperature increased—Dexamethasone—psoriasis	4.74e-05	0.000187	CcSEcCtD
Dasatinib—Body temperature increased—Betamethasone—psoriasis	4.74e-05	0.000187	CcSEcCtD
Dasatinib—Insomnia—Prednisone—psoriasis	4.73e-05	0.000186	CcSEcCtD
Dasatinib—Nausea—Cyclosporine—psoriasis	4.69e-05	0.000185	CcSEcCtD
Dasatinib—Pruritus—Triamcinolone—psoriasis	4.68e-05	0.000185	CcSEcCtD
Dasatinib—Cough—Methotrexate—psoriasis	4.67e-05	0.000184	CcSEcCtD
Dasatinib—Dizziness—Hydrocortisone—psoriasis	4.64e-05	0.000183	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—psoriasis	4.64e-05	0.000183	CcSEcCtD
Dasatinib—Dyspepsia—Prednisone—psoriasis	4.6e-05	0.000181	CcSEcCtD
Dasatinib—Nausea—Mycophenolate mofetil—psoriasis	4.58e-05	0.000181	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—psoriasis	4.56e-05	0.00018	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—psoriasis	4.56e-05	0.00018	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—psoriasis	4.56e-05	0.00018	CcSEcCtD
Dasatinib—Decreased appetite—Prednisone—psoriasis	4.54e-05	0.000179	CcSEcCtD
Dasatinib—Rash—Prednisolone—psoriasis	4.53e-05	0.000179	CcSEcCtD
Dasatinib—Dermatitis—Prednisolone—psoriasis	4.53e-05	0.000179	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.52e-05	0.000178	CcSEcCtD
Dasatinib—Fatigue—Prednisone—psoriasis	4.51e-05	0.000178	CcSEcCtD
Dasatinib—Headache—Prednisolone—psoriasis	4.51e-05	0.000178	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—psoriasis	4.5e-05	0.000177	CcSEcCtD
Dasatinib—Constipation—Prednisone—psoriasis	4.47e-05	0.000176	CcSEcCtD
Dasatinib—Vomiting—Hydrocortisone—psoriasis	4.47e-05	0.000176	CcSEcCtD
Dasatinib—Rash—Hydrocortisone—psoriasis	4.43e-05	0.000175	CcSEcCtD
Dasatinib—Dermatitis—Hydrocortisone—psoriasis	4.42e-05	0.000174	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—psoriasis	4.4e-05	0.000174	CcSEcCtD
Dasatinib—Headache—Hydrocortisone—psoriasis	4.4e-05	0.000174	CcSEcCtD
Dasatinib—Dizziness—Triamcinolone—psoriasis	4.37e-05	0.000172	CcSEcCtD
Dasatinib—Infection—Methotrexate—psoriasis	4.34e-05	0.000171	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisone—psoriasis	4.31e-05	0.00017	CcSEcCtD
Dasatinib—Asthenia—Betamethasone—psoriasis	4.31e-05	0.00017	CcSEcCtD
Dasatinib—Asthenia—Dexamethasone—psoriasis	4.31e-05	0.00017	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—psoriasis	4.28e-05	0.000169	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—psoriasis	4.28e-05	0.000169	CcSEcCtD
Dasatinib—Gastrointestinal pain—Prednisone—psoriasis	4.27e-05	0.000169	CcSEcCtD
Dasatinib—Nausea—Prednisolone—psoriasis	4.27e-05	0.000168	CcSEcCtD
Dasatinib—Pruritus—Betamethasone—psoriasis	4.25e-05	0.000167	CcSEcCtD
Dasatinib—Pruritus—Dexamethasone—psoriasis	4.25e-05	0.000167	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—psoriasis	4.24e-05	0.000167	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—psoriasis	4.22e-05	0.000166	CcSEcCtD
Dasatinib—Vomiting—Triamcinolone—psoriasis	4.21e-05	0.000166	CcSEcCtD
Dasatinib—Nausea—Hydrocortisone—psoriasis	4.17e-05	0.000165	CcSEcCtD
Dasatinib—Rash—Triamcinolone—psoriasis	4.17e-05	0.000164	CcSEcCtD
Dasatinib—Dermatitis—Triamcinolone—psoriasis	4.17e-05	0.000164	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—psoriasis	4.16e-05	0.000164	CcSEcCtD
Dasatinib—Urticaria—Prednisone—psoriasis	4.15e-05	0.000164	CcSEcCtD
Dasatinib—Headache—Triamcinolone—psoriasis	4.14e-05	0.000163	CcSEcCtD
Dasatinib—Abdominal pain—Prednisone—psoriasis	4.13e-05	0.000163	CcSEcCtD
Dasatinib—Body temperature increased—Prednisone—psoriasis	4.13e-05	0.000163	CcSEcCtD
Dasatinib—Diarrhoea—Betamethasone—psoriasis	4.11e-05	0.000162	CcSEcCtD
Dasatinib—Diarrhoea—Dexamethasone—psoriasis	4.11e-05	0.000162	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—psoriasis	4.08e-05	0.000161	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—psoriasis	3.98e-05	0.000157	CcSEcCtD
Dasatinib—Dizziness—Betamethasone—psoriasis	3.97e-05	0.000156	CcSEcCtD
Dasatinib—Dizziness—Dexamethasone—psoriasis	3.97e-05	0.000156	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—psoriasis	3.95e-05	0.000156	CcSEcCtD
Dasatinib—Nausea—Triamcinolone—psoriasis	3.93e-05	0.000155	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—psoriasis	3.89e-05	0.000154	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—psoriasis	3.88e-05	0.000153	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisone—psoriasis	3.85e-05	0.000152	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—psoriasis	3.84e-05	0.000152	CcSEcCtD
Dasatinib—Vomiting—Dexamethasone—psoriasis	3.82e-05	0.00015	CcSEcCtD
Dasatinib—Vomiting—Betamethasone—psoriasis	3.82e-05	0.00015	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—psoriasis	3.8e-05	0.00015	CcSEcCtD
Dasatinib—Rash—Betamethasone—psoriasis	3.78e-05	0.000149	CcSEcCtD
Dasatinib—Rash—Dexamethasone—psoriasis	3.78e-05	0.000149	CcSEcCtD
Dasatinib—Dermatitis—Betamethasone—psoriasis	3.78e-05	0.000149	CcSEcCtD
Dasatinib—Dermatitis—Dexamethasone—psoriasis	3.78e-05	0.000149	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—psoriasis	3.77e-05	0.000149	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—psoriasis	3.77e-05	0.000148	CcSEcCtD
Dasatinib—Headache—Dexamethasone—psoriasis	3.76e-05	0.000148	CcSEcCtD
Dasatinib—Headache—Betamethasone—psoriasis	3.76e-05	0.000148	CcSEcCtD
Dasatinib—Asthenia—Prednisone—psoriasis	3.75e-05	0.000148	CcSEcCtD
Dasatinib—Pain—Methotrexate—psoriasis	3.74e-05	0.000147	CcSEcCtD
Dasatinib—Pruritus—Prednisone—psoriasis	3.7e-05	0.000146	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—psoriasis	3.6e-05	0.000142	CcSEcCtD
Dasatinib—Diarrhoea—Prednisone—psoriasis	3.58e-05	0.000141	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—psoriasis	3.57e-05	0.000141	CcSEcCtD
Dasatinib—Nausea—Betamethasone—psoriasis	3.56e-05	0.000141	CcSEcCtD
Dasatinib—Nausea—Dexamethasone—psoriasis	3.56e-05	0.000141	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—psoriasis	3.47e-05	0.000137	CcSEcCtD
Dasatinib—Dizziness—Prednisone—psoriasis	3.46e-05	0.000136	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—psoriasis	3.45e-05	0.000136	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—psoriasis	3.45e-05	0.000136	CcSEcCtD
Dasatinib—Vomiting—Prednisone—psoriasis	3.32e-05	0.000131	CcSEcCtD
Dasatinib—Rash—Prednisone—psoriasis	3.3e-05	0.00013	CcSEcCtD
Dasatinib—Dermatitis—Prednisone—psoriasis	3.29e-05	0.00013	CcSEcCtD
Dasatinib—Headache—Prednisone—psoriasis	3.27e-05	0.000129	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—psoriasis	3.22e-05	0.000127	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—psoriasis	3.13e-05	0.000124	CcSEcCtD
Dasatinib—Nausea—Prednisone—psoriasis	3.1e-05	0.000122	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—psoriasis	3.09e-05	0.000122	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—psoriasis	2.99e-05	0.000118	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—psoriasis	2.89e-05	0.000114	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—psoriasis	2.78e-05	0.00011	CcSEcCtD
Dasatinib—Rash—Methotrexate—psoriasis	2.75e-05	0.000109	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—psoriasis	2.75e-05	0.000108	CcSEcCtD
Dasatinib—Headache—Methotrexate—psoriasis	2.74e-05	0.000108	CcSEcCtD
Dasatinib—Nausea—Methotrexate—psoriasis	2.59e-05	0.000102	CcSEcCtD
Dasatinib—RIPK2—Signaling Pathways—JUN—psoriasis	4.94e-06	2.31e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD4—psoriasis	4.92e-06	2.31e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—psoriasis	4.9e-06	2.3e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD4—psoriasis	4.9e-06	2.29e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—psoriasis	4.9e-06	2.29e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NFKBIA—psoriasis	4.87e-06	2.28e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ICAM1—psoriasis	4.86e-06	2.28e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CXCL8—psoriasis	4.86e-06	2.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—CXCL8—psoriasis	4.85e-06	2.27e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD4—psoriasis	4.84e-06	2.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—psoriasis	4.84e-06	2.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IFNG—psoriasis	4.83e-06	2.26e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NFKBIA—psoriasis	4.82e-06	2.26e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—APOE—psoriasis	4.81e-06	2.25e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—NFKB1—psoriasis	4.81e-06	2.25e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—APOE—psoriasis	4.78e-06	2.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IFNG—psoriasis	4.77e-06	2.23e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NFKB1—psoriasis	4.75e-06	2.23e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TYK2—psoriasis	4.72e-06	2.21e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—LEP—psoriasis	4.71e-06	2.21e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—APOE—psoriasis	4.71e-06	2.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—TYK2—psoriasis	4.7e-06	2.2e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CXCL8—psoriasis	4.68e-06	2.19e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—psoriasis	4.67e-06	2.19e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD4—psoriasis	4.67e-06	2.19e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—psoriasis	4.65e-06	2.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CD4—psoriasis	4.64e-06	2.17e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—psoriasis	4.61e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—LEP—psoriasis	4.61e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—APOE—psoriasis	4.61e-06	2.16e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD4—psoriasis	4.61e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—psoriasis	4.57e-06	2.14e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—STAT3—psoriasis	4.56e-06	2.14e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—psoriasis	4.55e-06	2.13e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—psoriasis	4.54e-06	2.13e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—LEP—psoriasis	4.54e-06	2.13e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—APOE—psoriasis	4.54e-06	2.13e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SOCS1—psoriasis	4.53e-06	2.12e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—psoriasis	4.52e-06	2.12e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—JUN—psoriasis	4.51e-06	2.11e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—psoriasis	4.51e-06	2.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—JUN—psoriasis	4.5e-06	2.11e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—psoriasis	4.5e-06	2.11e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CD4—psoriasis	4.47e-06	2.1e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—TYK2—psoriasis	4.46e-06	2.09e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS2—psoriasis	4.45e-06	2.09e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—psoriasis	4.44e-06	2.08e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—psoriasis	4.42e-06	2.07e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—JUN—psoriasis	4.4e-06	2.06e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	4.39e-06	2.06e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—JUN—psoriasis	4.38e-06	2.05e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—APOE—psoriasis	4.38e-06	2.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—LEP—psoriasis	4.37e-06	2.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—APOE—psoriasis	4.37e-06	2.05e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—psoriasis	4.36e-06	2.04e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—JUN—psoriasis	4.35e-06	2.04e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	4.34e-06	2.04e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—JUN—psoriasis	4.34e-06	2.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—psoriasis	4.33e-06	2.03e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—NFKB1—psoriasis	4.33e-06	2.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—STAT3—psoriasis	4.32e-06	2.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—APOE—psoriasis	4.31e-06	2.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—LEP—psoriasis	4.31e-06	2.02e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—VEGFA—psoriasis	4.31e-06	2.02e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NFKBIA—psoriasis	4.3e-06	2.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—psoriasis	4.28e-06	2e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—STAT3—psoriasis	4.27e-06	2e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CD4—psoriasis	4.25e-06	1.99e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.24e-06	1.99e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NFKB1—psoriasis	4.24e-06	1.99e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NFKBIA—psoriasis	4.23e-06	1.98e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NFKB1—psoriasis	4.22e-06	1.98e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TYK2—psoriasis	4.21e-06	1.97e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—STAT3—psoriasis	4.21e-06	1.97e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PPARG—psoriasis	4.19e-06	1.96e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NFKB1—psoriasis	4.19e-06	1.96e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IFNG—psoriasis	4.18e-06	1.96e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—JUN—psoriasis	4.18e-06	1.96e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—NFKB1—psoriasis	4.17e-06	1.96e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—psoriasis	4.12e-06	1.93e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—JUN—psoriasis	4.12e-06	1.93e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—TYK2—psoriasis	4.12e-06	1.93e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CXCL8—psoriasis	4.11e-06	1.92e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NFKBIA—psoriasis	4.07e-06	1.91e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—psoriasis	4.07e-06	1.9e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CAT—psoriasis	4.04e-06	1.89e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD4—psoriasis	4.03e-06	1.89e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—psoriasis	4.02e-06	1.88e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NFKBIA—psoriasis	4.02e-06	1.88e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NFKB1—psoriasis	4.02e-06	1.88e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—psoriasis	3.99e-06	1.87e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TYK2—psoriasis	3.99e-06	1.87e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—STAT3—psoriasis	3.99e-06	1.87e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NFKB1—psoriasis	3.97e-06	1.86e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CARM1—psoriasis	3.95e-06	1.85e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—TYK2—psoriasis	3.95e-06	1.85e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	3.94e-06	1.85e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—STAT3—psoriasis	3.9e-06	1.83e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—STAT3—psoriasis	3.89e-06	1.82e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—JUN—psoriasis	3.82e-06	1.79e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CAT—psoriasis	3.81e-06	1.79e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PPARG—psoriasis	3.81e-06	1.79e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—STAT3—psoriasis	3.81e-06	1.78e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—psoriasis	3.8e-06	1.78e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—STAT3—psoriasis	3.79e-06	1.78e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—LEP—psoriasis	3.78e-06	1.77e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—APOE—psoriasis	3.78e-06	1.77e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—STAT3—psoriasis	3.76e-06	1.76e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—psoriasis	3.75e-06	1.76e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—psoriasis	3.75e-06	1.76e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—STAT3—psoriasis	3.75e-06	1.76e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—psoriasis	3.75e-06	1.75e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CD4—psoriasis	3.72e-06	1.74e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IFNG—psoriasis	3.7e-06	1.73e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.7e-06	1.73e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NFKB1—psoriasis	3.68e-06	1.72e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CXCL8—psoriasis	3.67e-06	1.72e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TYK2—psoriasis	3.65e-06	1.71e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—STAT3—psoriasis	3.61e-06	1.69e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—JUN—psoriasis	3.61e-06	1.69e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TYK2—psoriasis	3.59e-06	1.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—STAT3—psoriasis	3.59e-06	1.68e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD4—psoriasis	3.57e-06	1.67e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—psoriasis	3.57e-06	1.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—STAT3—psoriasis	3.57e-06	1.67e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NFKBIA—psoriasis	3.52e-06	1.65e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TYK2—psoriasis	3.52e-06	1.65e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NFKB1—psoriasis	3.48e-06	1.63e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	3.47e-06	1.63e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TYK2—psoriasis	3.46e-06	1.62e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—STAT3—psoriasis	3.46e-06	1.62e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—JUN—psoriasis	3.41e-06	1.6e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—APOE—psoriasis	3.34e-06	1.57e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—LEP—psoriasis	3.34e-06	1.57e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—psoriasis	3.34e-06	1.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TYK2—psoriasis	3.34e-06	1.56e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—psoriasis	3.32e-06	1.55e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—STAT3—psoriasis	3.3e-06	1.55e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CD4—psoriasis	3.3e-06	1.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TYK2—psoriasis	3.29e-06	1.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—STAT3—psoriasis	3.29e-06	1.54e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NFKB1—psoriasis	3.28e-06	1.54e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—psoriasis	3.26e-06	1.53e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—JUN—psoriasis	3.23e-06	1.51e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—JUN—psoriasis	3.2e-06	1.5e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—psoriasis	3.19e-06	1.49e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—APOE—psoriasis	3.14e-06	1.47e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	3.13e-06	1.47e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—STAT3—psoriasis	3.12e-06	1.46e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NFKBIA—psoriasis	3.12e-06	1.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	3.11e-06	1.46e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NFKB1—psoriasis	3.08e-06	1.44e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL8—psoriasis	3.06e-06	1.44e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CARM1—psoriasis	3.05e-06	1.43e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAT—psoriasis	3.05e-06	1.43e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—psoriasis	3.02e-06	1.41e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL8—psoriasis	3.02e-06	1.41e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—psoriasis	2.98e-06	1.4e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—psoriasis	2.98e-06	1.4e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—psoriasis	2.98e-06	1.4e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOE—psoriasis	2.96e-06	1.39e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—psoriasis	2.95e-06	1.38e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—psoriasis	2.94e-06	1.38e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—JUN—psoriasis	2.91e-06	1.36e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—psoriasis	2.9e-06	1.36e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TYK2—psoriasis	2.88e-06	1.35e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—psoriasis	2.88e-06	1.35e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—psoriasis	2.87e-06	1.35e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—psoriasis	2.87e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—JUN—psoriasis	2.85e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	2.82e-06	1.32e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—JUN—psoriasis	2.8e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	2.8e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—psoriasis	2.79e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—psoriasis	2.79e-06	1.31e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—psoriasis	2.76e-06	1.3e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NFKB1—psoriasis	2.74e-06	1.28e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—psoriasis	2.73e-06	1.28e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—psoriasis	2.73e-06	1.28e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—psoriasis	2.73e-06	1.28e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—psoriasis	2.72e-06	1.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JUN—psoriasis	2.7e-06	1.26e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NFKB1—psoriasis	2.7e-06	1.26e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—JUN—psoriasis	2.66e-06	1.25e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—psoriasis	2.66e-06	1.25e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—psoriasis	2.65e-06	1.24e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—psoriasis	2.63e-06	1.23e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—psoriasis	2.62e-06	1.23e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NFKB1—psoriasis	2.6e-06	1.22e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—psoriasis	2.58e-06	1.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NFKB1—psoriasis	2.57e-06	1.2e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TYK2—psoriasis	2.55e-06	1.2e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—psoriasis	2.55e-06	1.2e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	2.54e-06	1.19e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—psoriasis	2.52e-06	1.18e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—psoriasis	2.52e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—psoriasis	2.52e-06	1.18e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—psoriasis	2.51e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—psoriasis	2.51e-06	1.18e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—psoriasis	2.49e-06	1.17e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—psoriasis	2.49e-06	1.17e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—psoriasis	2.46e-06	1.15e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—psoriasis	2.45e-06	1.15e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAT—psoriasis	2.43e-06	1.14e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—psoriasis	2.43e-06	1.14e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—psoriasis	2.42e-06	1.13e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOE—psoriasis	2.37e-06	1.11e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—psoriasis	2.36e-06	1.1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—psoriasis	2.34e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—psoriasis	2.33e-06	1.09e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—psoriasis	2.33e-06	1.09e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—psoriasis	2.31e-06	1.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—psoriasis	2.31e-06	1.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—psoriasis	2.3e-06	1.08e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—psoriasis	2.25e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NFKB1—psoriasis	2.25e-06	1.05e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—psoriasis	2.22e-06	1.04e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—psoriasis	2.18e-06	1.02e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—psoriasis	2.13e-06	9.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—psoriasis	2.07e-06	9.68e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—psoriasis	2.06e-06	9.66e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—psoriasis	2.06e-06	9.65e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—psoriasis	2.04e-06	9.55e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—psoriasis	2.02e-06	9.46e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—psoriasis	2.01e-06	9.44e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NFKB1—psoriasis	1.99e-06	9.32e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—psoriasis	1.95e-06	9.14e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—psoriasis	1.93e-06	9.05e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—psoriasis	1.92e-06	9e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOE—psoriasis	1.89e-06	8.85e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—psoriasis	1.88e-06	8.81e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAT—psoriasis	1.88e-06	8.79e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—psoriasis	1.85e-06	8.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—psoriasis	1.81e-06	8.46e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—psoriasis	1.79e-06	8.37e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—psoriasis	1.78e-06	8.35e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—psoriasis	1.78e-06	8.35e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—psoriasis	1.76e-06	8.24e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—psoriasis	1.76e-06	8.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—psoriasis	1.72e-06	8.06e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—psoriasis	1.69e-06	7.94e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—psoriasis	1.65e-06	7.71e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—psoriasis	1.63e-06	7.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—psoriasis	1.61e-06	7.54e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—psoriasis	1.54e-06	7.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOE—psoriasis	1.46e-06	6.83e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—psoriasis	1.41e-06	6.61e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—psoriasis	1.36e-06	6.39e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—psoriasis	1.27e-06	5.95e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—psoriasis	1.25e-06	5.85e-06	CbGpPWpGaD
